Spatial Engineering: The Design Era of Oncology

Precision oncology has progressed through three eras: the genomic era, which identified mutations and molecular circuits; the archetype era, which revealed recurring tumor ecosystems; and now the emerging engineering era, enabled by AI and spatial modeling, which allows the rational reprogramming of tissue architecture. We define Spatial Engineering as a framework that integrates cellular composition, topology, physical context, and clonality into a multidimensional control space, describing how architecture can be perturbed to destabilize malignancy or restore homeostasis. Many breakthrough therapies, including checkpoint inhibitors, anti-angiogenics, CAR-T cells, and bispecific antibodies, already act through spatial mechanisms, yet most were discovered empirically. Spatial Engineering reframes them within a predictive logic of tissue design: measure architecture, model stability, intervene with intent, and adapt in real time. Early clinical trials are beginning to use spatial archetypes to assign therapy; the next leap is AI-guided simulation of drug sequences and therapeutic windows to steer malignant equilibria toward collapse. Together, these advances complete oncology’s transition from mapping tumors to designing their cure.